Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTRB1 | P17538 | 3/20 | 0.50 |
| ▸ | MME | P08473 | 2/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | ALPI | P09923 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.48 |
| ▸ | XIAP | P98170 | 1/20 | 0.48 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.48 |
| ▸ | CTSC | P53634 | 2/20 | 0.47 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3730596 | 1.00 | CTRB1 (0.50) | CTRB1MMECYP3A4MAPK1NPC1 | |
| SCHEMBL14320632 | 1.00 | CTRB1 (0.50) | CTRB1MMECYP3A4MAPK1NPC1 | |
| Hydrochloric Acid SCHEMBL9732826 | 0.98 | MME (0.49) | CTRB1MMECYP3A4MAPK1NPC1 | |
| SCHEMBL5568036 | 0.86 | CTRB1 (0.57) | CTRB1CYP3A4MAPK1NPC1RAB9A | |
| SCHEMBL12294556 | 0.86 | CTRB1 (0.57) | CTRB1CYP3A4MAPK1NPC1RAB9A | |
| SCHEMBL20791696 | 0.86 | OPRK1 (0.55) | SLC7A5 | |
| SCHEMBL20791698 | 0.86 | OPRK1 (0.55) | SLC7A5 | |
| SCHEMBL18577288 | 0.84 | MME (0.49) | MMECYP3A4CTSCCYP1A2 | |
| SCHEMBL18577290 | 0.84 | MME (0.49) | MMECYP3A4CTSCCYP1A2 | |
| SCHEMBL3897966 | 0.83 | MAPK1 (0.68) | CTRB1MMECYP3A4MAPK1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3743430-B1 | AMINOPYRROLOTRIAZINES AS KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2023-08-02 | — | — | EP | disclosed |
| US-11618753-B2 | Aminopyrrolotriazines as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-04-04 | — | — | US | disclosed |
| US-20220401401-A1 | CARBAMOYL PHENYLALANINOL ANALOGS AND USES THEREOF | HERCULES CAPITAL, INC. | 2022-12-22 | — | — | US | disclosed |
| US-20210093603-A1 | CARBAMOYL PHENYLALANINOL ANALOGS AND USES THEREOF | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2021-04-01 | — | — | US | disclosed |
| EP-3743430-A1 | AMINOPYRROLOTRIAZINES AS KINASE INHIBITORS | Bristol-Myers Squibb Company (US) | 2020-12-02 | — | — | EP | disclosed |
| US-20200347071-A1 | AMINOPYRROLOTRIAZINES AS KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2020-11-05 | — | — | US | disclosed |
| WO-2019147782-A1 | AMINOPYRROLOTRIAZINES AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-08-01 | — | — | WO | disclosed |
| CN-105102456-B | Azaquinazoline inhibitors of atypical protein kinase C | 癌症研究技术有限公司 | 2017-11-14 | — | — | CN | disclosed |
| US-20170198006-A1 | PRMT5 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2017-07-13 | — | — | US | disclosed |
| EP-3160477-A2 | PRMT5 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2017-05-03 | — | — | EP | disclosed |
| WO-2015200680-A2 | PRMT5 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2015-12-30 | — | — | WO | disclosed |
| CN-105102456-A | Azaquinazoline inhibitors of atypical protein kinase C | IGNYTA INC | 2015-11-25 | — | — | CN | disclosed |
| EP-2555623-A1 | FLAVIN DERIVATIVES | BioRelix, Inc. (US) | 2013-02-13 | — | — | EP | disclosed |
| US-20130029980-A1 | FLAVIN DERIVATIVES | COISH PHILIP D G (US) | 2013-01-31 | — | — | US | disclosed |
| WO-2011126567-A1 | FLAVIN DERIVATIVES | BIORELIX, INC. (US) | 2011-10-13 | — | — | WO | disclosed |
| US-5173510-A | Anticholesterol agents | AMERICAN CYANAMID COMPANY (US) | 1992-12-22 | — | — | US | disclosed |
| US-5053426-A | Enzyme inhibitors | AMERICAN CYANAMID COMPANY (US) | 1991-10-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130029980-A1 | FLAVIN DERIVATIVES | BLVRB, FLAD1, FDPS | CTRB1 1419/4885MME 3708/4885CYP3A4 547/4885 |
| US-20200347071-A1 | AMINOPYRROLOTRIAZINES AS KINASE INHIBITORS | RIPK1, RIPK2, RIPK4 | CTRB1 4097/4885MME 4505/4885CYP3A4 3862/4885 |
| US-20210093603-A1 | CARBAMOYL PHENYLALANINOL ANALOGS AND USES THEREOF | DNPEP, CPS1, GLS | CTRB1 139/4885MME 344/4885CYP3A4 1670/4885 |
| US-20220401401-A1 | CARBAMOYL PHENYLALANINOL ANALOGS AND USES THEREOF | DNPEP, CPS1, GLS | CTRB1 139/4885MME 344/4885CYP3A4 1670/4885 |
| US-20170198006-A1 | PRMT5 INHIBITORS AND USES THEREOF | PRMT5, PRMT1, PRMT6 | CTRB1 4552/4885MME 3970/4885CYP3A4 2610/4885 |
| US-11618753-B2 | Aminopyrrolotriazines as kinase inhibitors | RIPK1, RIPK2, RIPK4 | CTRB1 4097/4885MME 4505/4885CYP3A4 3862/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.